Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look [Seeking Alpha]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Seeking Alpha
There are four other data readouts/presentations expected in 2024, which relate to the use of zerlasiran for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease. The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032; Targeting lipoprotein[a] for cardiovascular disease is an unmet need. Another candidate in its pipeline would be divesiran, which is being advanced in the phase 1 SANRECO-PV study treating patients with polycythemia vera; Results from this study are expected to be released in mid-2024. Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More » Silence Therapeutics NASDAQ: SLN ) is gearing up to report topline 36-week data from its phase 2 ALPACAR-360 study, which is using its drug zerlasiran [formerly known as SLN360] for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceBusiness Wire
- Bitterroot Bio kickstarts Phase I trial for cardiovascular disease candidate [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsBusiness Wire
- Silence Therapeutics plc (NASDAQ: SLN) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $45.00 price target on the stock.MarketBeat
SLN
Sec Filings
- 5/1/24 - Form 6-K
- 4/29/24 - Form 6-K
- 4/15/24 - Form 6-K
- SLN's page on the SEC website